Quantum BioPharma Completes Warrant Expiration and Confirms CVR Record Date for Potential Litigation Proceeds

Quantum BioPharma Ltd. announced the expiration at 5 p.m. ET of 53,147 warrants originally issued to hedge funds and investment funds as part of a 2020 financing arrangement. These warrants represented the final tranche of such instruments, having been reduced from 3,454,543 pre-reverse-split warrants. The company simultaneously reaffirmed October 27, 2025 as the record date for the distribution of contingent value rights to Class B Subordinate Voting Shareholders on a one-for-one basis.

The contingent value rights entitle holders to a potential pro rata share of 10% to 50% of any net proceeds from Quantum BioPharma's $700 million litigation against CIBC World Markets, RBC Dominion Securities, and other defendants. This litigation represents a significant potential financial opportunity for shareholders beyond the company's core biopharmaceutical operations. The warrant expiration and CVR confirmation represent important corporate milestones that could impact shareholder value and the company's financial position.

Quantum BioPharma maintains a diverse business strategy that includes its core biopharmaceutical research through subsidiary Lucid Psycheceuticals Inc., which focuses on developing Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Myelin degradation represents the underlying mechanism of multiple sclerosis, positioning the company in the neurodegenerative disease treatment space. Additional information about the company's developments can be found at https://ibn.fm/QNTM.

The company also maintains strategic interests in consumer health products through its ownership stake in Unbuzzd Wellness Inc., retaining 20.11% ownership as of March 31, 2025, along with royalty arrangements that include 7% of sales from unbuzzd products until payments to Quantum BioPharma total $250 million, after which the royalty decreases to 3% in perpetuity. Quantum BioPharma retains full rights to develop similar products for pharmaceutical and medical applications. Further corporate information is available through the company's newsroom at https://ibn.fm/g52XC.

These corporate developments occur within the broader context of Quantum BioPharma's focus on treating challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, with drug candidates in various development stages. The resolution of the warrant obligations and the establishment of clear parameters for the CVR distribution provide shareholders with increased clarity regarding potential future value from both the company's litigation efforts and its core biopharmaceutical research initiatives.